The late filing, while accompanied by a dramatically improved net loss estimate, signals ongoing accounting complexity and potential audit delays. Monitor the actual 10-K filing for auditor opinion, cash runway, and any going-concern language. The company's history of name changes and restructuring suggests continued operational risk.
Price Chart
Executive Summary
Lunai Bioworks filed an NT 10-K, notifying the SEC that it cannot file its annual report for the fiscal year ended June 30, 2026 on time, citing unreasonable effort or expense. The company expects to file within the 15-day grace period. Preliminary estimates show a net loss of ~$3.2M for FY2026, a dramatic improvement from the ~$178.0M loss in FY2025, driven by the absence of a large goodwill impairment and restructuring savings, but offset by debt extinguishment losses and contingent consideration fair value changes.
Key Financial Metrics
Key Facts
- NT 10-K filed for FY ended June 30, 2026; expects to file within 15-day grace period.
- Preliminary net loss of ~$3.2M for FY2026 vs. ~$178.0M loss in FY2025.
- Improvement driven by absence of ~$170.4M goodwill impairment, ~$10.4M G&A reduction, and ~$12.0M gain from deconsolidation of GEDi Cube B.V.
- Offset by ~$7.4M loss on debt extinguishment, ~$0.832M impairment of long-lived assets, and ~$11.1M unfavorable change in contingent consideration fair value.
- Company has undergone multiple name changes (formerly Renovaro Inc., Renovaro Biosciences Inc., Enochian Biosciences Inc.).
Financial Impact
Preliminary net loss of ~$3.2M for FY2026 vs. ~$178.0M loss in FY2025; key drivers include ~$170.4M goodwill impairment absence, ~$10.4M G&A reduction, ~$12.0M deconsolidation gain, ~$7.4M debt extinguishment loss, ~$0.832M asset impairment, and ~$11.1M contingent consideration change.
Risk Factors
- Late filing may trigger debt covenant violations or SEC scrutiny.
- Preliminary estimates are unaudited and subject to material revision.
- Company has a history of restructuring, debt exchanges, and subsidiary bankruptcy (GEDi Cube B.V.).
- Potential for auditor change or restatement if audit uncovers issues.
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| NT 10-K Filing (Primary) | 0001731122-26-001299 |
| Document: 0001731122-26-001299-index-headers.html | 0001731122-26-001299 |
| Document: 0001731122-26-001299-index.html | 0001731122-26-001299 |
| Document: 0001731122-26-001299.txt | 0001731122-26-001299 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 3d ago | 8-K | $0.2946 $0.2750 | ▲ +6.65% | ▲ +7.36% | $0.2750 (+6.65%) |
Oct 15, 2026 10d ago | SC 13D/A | $0.6800 $0.4720 | ▲ +30.59% | ▲ +31.01% | $0.2750 (+59.56%) |
Oct 9, 2026 17d ago | 8-K | $1.23 $1.11 | ▲ +9.76% | ▲ +9.70% | $0.2750 (+77.64%) |
Sep 29, 2026 27d ago | NT 10-K | $1.47 $1.38 | ▲ +6.12% | ▲ +6.30% | $0.2750 (+81.29%) |
Jun 17, 2026 18w ago | 8-K | $3.78 $4.15 | ▲ +9.79% | ▲ +10.10% | $0.2750 (−92.72%) |
Jun 16, 2026 18w ago | 8-K | $4.00 $3.78 | ▼ −5.50% | ▼ −6.28% | $0.2750 (−93.12%) |
May 20, 2026 22w ago | 8-K | $1.80 $2.32 | ▼ −28.89% | ▼ −28.69% | $0.2750 (+84.72%) |
May 1, 2026 25w ago | 8-K | $2.60 $2.50 | ▼ −3.88% | ▼ −4.68% | $0.2750 (−89.41%) |
Apr 28, 2026 25w ago | DEFA14A | $2.66 $2.64 | ▼ −0.90% | ▼ −1.92% | $0.2750 (−89.68%) |
Mar 5, 2026 33w ago | 8-K | $1.86 $1.76 | ▲ +5.25% | ▲ +6.10% | $0.2750 (+85.20%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers